CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges
Abstract. Chimeric antigen receptor T (CAR-T) cell therapy, renowned for its successes in cancer treatment, is now entering the field of human immunodeficiency virus (HIV) therapy, presenting both opportunities and challenges. With the emergence of broadly neutralizing antibodies, multi-target CARs,...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health - Lippincott Williams Wilkins
2024-10-01
|
| Series: | Infectious Diseases & Immunity |
| Online Access: | http://journals.lww.com/10.1097/ID9.0000000000000129 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850283002286833664 |
|---|---|
| author | Xiao Wang Jianyang Liu Feike Hao Tatchapon Ajavavarakula Xuanling Shi Haijuan Wang |
| author_facet | Xiao Wang Jianyang Liu Feike Hao Tatchapon Ajavavarakula Xuanling Shi Haijuan Wang |
| author_sort | Xiao Wang |
| collection | DOAJ |
| description | Abstract. Chimeric antigen receptor T (CAR-T) cell therapy, renowned for its successes in cancer treatment, is now entering the field of human immunodeficiency virus (HIV) therapy, presenting both opportunities and challenges. With the emergence of broadly neutralizing antibodies, multi-target CARs, and T cell receptor–like antibodies aimed at increasing specificity in targeting HIV reservoirs, CAR-T therapy is synergizing with other cutting-edge treatments, including gene-editing technologies, therapeutic vaccines, and latency-reversing agents, in pursuit of a potential functional cure. In this review, we delve into the role of CAR-T therapy in HIV treatment, highlighting its potential to overcome clinical obstacles. We discuss advancements in targeting strategies within CAR constructs and the intricate regulation of T cell proliferation and chemotaxis. Moreover, we explore the use of diverse immune cells, such as gamma-delta T cells and natural killer cells. We review advanced biotechnologies, manufacturing innovations, viral mechanisms, and immune microenvironments. We also discuss the current research landscape and potential future applications of CAR-T therapy against HIV, which remains a critical global health challenge. |
| format | Article |
| id | doaj-art-4a1e2e8a72ac4394858bc7500a439964 |
| institution | OA Journals |
| issn | 2096-9511 2693-8839 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Wolters Kluwer Health - Lippincott Williams Wilkins |
| record_format | Article |
| series | Infectious Diseases & Immunity |
| spelling | doaj-art-4a1e2e8a72ac4394858bc7500a4399642025-08-20T01:47:51ZengWolters Kluwer Health - Lippincott Williams WilkinsInfectious Diseases & Immunity2096-95112693-88392024-10-014419420510.1097/ID9.0000000000000129202410000-00008CAR-T Therapy in HIV: Pioneering Advances and Navigating ChallengesXiao Wang0Jianyang Liu1Feike Hao2Tatchapon Ajavavarakula3Xuanling Shi4Haijuan Wang1 School of Basic Medical Sciences, Tsinghua University, Beijing 100084, China2 Tsingmed Therapeutic Technology Co., Ltd., Beijing 100084, China1 School of Basic Medical Sciences, Tsinghua University, Beijing 100084, China3 School of Life Sciences, Tsinghua University, Beijing 100084, China1 School of Basic Medical Sciences, Tsinghua University, Beijing 100084, ChinaAbstract. Chimeric antigen receptor T (CAR-T) cell therapy, renowned for its successes in cancer treatment, is now entering the field of human immunodeficiency virus (HIV) therapy, presenting both opportunities and challenges. With the emergence of broadly neutralizing antibodies, multi-target CARs, and T cell receptor–like antibodies aimed at increasing specificity in targeting HIV reservoirs, CAR-T therapy is synergizing with other cutting-edge treatments, including gene-editing technologies, therapeutic vaccines, and latency-reversing agents, in pursuit of a potential functional cure. In this review, we delve into the role of CAR-T therapy in HIV treatment, highlighting its potential to overcome clinical obstacles. We discuss advancements in targeting strategies within CAR constructs and the intricate regulation of T cell proliferation and chemotaxis. Moreover, we explore the use of diverse immune cells, such as gamma-delta T cells and natural killer cells. We review advanced biotechnologies, manufacturing innovations, viral mechanisms, and immune microenvironments. We also discuss the current research landscape and potential future applications of CAR-T therapy against HIV, which remains a critical global health challenge.http://journals.lww.com/10.1097/ID9.0000000000000129 |
| spellingShingle | Xiao Wang Jianyang Liu Feike Hao Tatchapon Ajavavarakula Xuanling Shi Haijuan Wang CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges Infectious Diseases & Immunity |
| title | CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges |
| title_full | CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges |
| title_fullStr | CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges |
| title_full_unstemmed | CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges |
| title_short | CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges |
| title_sort | car t therapy in hiv pioneering advances and navigating challenges |
| url | http://journals.lww.com/10.1097/ID9.0000000000000129 |
| work_keys_str_mv | AT xiaowang carttherapyinhivpioneeringadvancesandnavigatingchallenges AT jianyangliu carttherapyinhivpioneeringadvancesandnavigatingchallenges AT feikehao carttherapyinhivpioneeringadvancesandnavigatingchallenges AT tatchaponajavavarakula carttherapyinhivpioneeringadvancesandnavigatingchallenges AT xuanlingshi carttherapyinhivpioneeringadvancesandnavigatingchallenges AT haijuanwang carttherapyinhivpioneeringadvancesandnavigatingchallenges |